Parenteral Pharmaceutical Formulation In Suspension, Having Sustained Release, In Low And Ultralow Dosage, In Hormonal Therapy In The Climacteric Syndrome

Patent No. EP2520301 (titled "Parenteral Pharmaceutical Formulation In Suspension, Having Sustained Release, In Low And Ultralow Dosage, In Hormonal Therapy In The Climacteric Syndrome") was filed by Techsphere on Dec 14, 2010. The application was issued on Mar 3, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BESINS HEALTHCARE MONACO SAMFeb 8, 2018NEDERLANDSCH OCTROOIBUREAU

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2520301

TECHSPHERE
Application Number
EP10837927A
Filing Date
Dec 14, 2010
Status
Patent Maintained As Amended
Jan 29, 2021
Publication Date
Mar 3, 2021